STAMFORD, CT – Sept. 22, 2026 – Knoa Pharma LLC (“Knoa Pharma”), a public health-focused pharmaceutical company dedicated to supporting patients and improving public health, will present its investigational pipeline assets at the 2026 LSX Congress USA in Boston, Massachusetts on September 23, at 1:45 p.m. ET, on the Biotech Growth stage. Knoa Pharma is actively seeking partnerships to advance the development of investigational therapeutics for multiple assets across several disease areas including genitourinary disorders, substance use disorders, and oncology. The company is discussing two assets, sunobinop and tinostamustine, both of which could present substantial revenue opportunities.*  

Tinostamustine is a novel, first-in-class investigational drug combining DNA alkylating activity and HDAC inhibition in a single molecule. It has the potential to be a first-line agent to treat patients with glioblastoma (GBM), a highly aggressive form of brain cancer. In Phase 1 studies as an adjuvant to standard chemoradiation, tinostamustine showed promising activity in difficult-to-treat newly diagnosed patients. The drug has received orphan drug designation from FDA and has the potential to be the first new pharmacologic treatment option for GBM in more than 20 years. In Phase 1/2 clinical trials, tinostamustine has also shown promise in multiple other solid and hematological tumors.

Currently, tinostamustine is also a part of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447), sponsored by the Global Coalition for Adaptive Research. This is a seamless phase 2/3 study conducted under a master protocol enabling multiple therapies or combinations of therapies to be evaluated simultaneously against a shared control arm. With its innovative design and efficient operational infrastructure, data from GBM AGILE can potentially be used as the foundation for new drug applications and registrations to the U.S. FDA and other health authorities.

Sunobinop is a novel, first-in-class nociceptin receptor agonist. The orally active investigational drug is in Phase 1/2 clinical development for multiple indications, including alcohol use disorder (AUD), interstitial cystitis/bladder pain syndrome (IC/BPS), and overactive bladder (OAB). Related to AUD, sunobinop is intended to address alcohol craving, consumption, and sleep issues; it has the potential to be the first new modality in AUD in almost 20 years. Related to OAB and IC/BPS, sunobinop is a novel, first-in-class agent that targets the sensory nerves in the bladder to affect urination and pain, and potentially reducing nocturia.

“Our R&D is grounded in rigorous science. Sunobinop and tinostamustine are differentiated, clinical-stage assets with encouraging signals across several disease areas,” said David Saussy, Head of Licensing and Business Development at Knoa Pharma. “We look forward to sharing Knoa Pharma’s pipeline and connecting with potential partners at LSX USA who share our commitment to advancing scientific innovation.”

Companies interested in learning more about Knoa Pharma’s pipeline and partnership opportunities are encouraged to connect with the team during LSX Congress USA 2026. For more information on pipeline products, e-mail partnering@pharma.com.

*This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that sunobinop or tinostamustine will successfully complete development or gain FDA approval. 

About Knoa Pharma LLC
Knoa Pharma was founded with a public health purpose to help abate the opioid crisis. That mission drives everything we do. We expand access to lifesaving overdose reversal medicines and deliver affordable treatments for opioid use disorder, while ensuring the safe and responsible distribution of medicines that are critical to patient care, including opioid analgesics. We also innovate to address unmet patient needs and enhance our robust generics portfolio. Owned by a not-for-profit foundation, every aspect of the business is centered on improving public health, saving lives, supporting recovery, and bringing forward medicines that make a meaningful difference. Learn more at www.knoapharma.com.

Media Contact:
News@pharma.com

The post Knoa Pharma to Present Pipeline Assets at LSX Congress USA 2026 appeared first on Knoa Pharma.

“Michael is a globally respected pharmaceutical leader who brings to Knoa Pharma more than 30 years of experience guiding organizations with a commitment to excellence. We are confident that under his leadership, Knoa Pharma will be well positioned to advance its public health purpose while responsibly meeting the needs of patients,” said Dr. Norbert Riedel, Chairman of the Board of Knoa Pharma. 

Goettler most recently served as CEO of Viatris, a global healthcare company. Throughout his career, Goettler has built and scaled innovative pharmaceutical businesses. His leadership experience spans commercial operations, R&D, medical affairs, and global markets. He has held senior roles at leading companies including Sanofi and Pfizer. 

“I am honored to join Knoa Pharma at such an important moment,” said Goettler. “This is a company defined by its purpose to help abate the opioid crisis, a mission that shapes everything it does, from how it serves patients to how it engages with communities. That commitment aligns deeply with my belief that pharmaceutical companies should be a force for good. I look forward to working alongside the talented team at Knoa to advance this mission, build a sustainable business, and make a meaningful difference for patients and communities across the country.” 

In addition to serving as President and CEO, Goettler will serve as the fifth member of the Knoa Pharma Board. More information about the Knoa Pharma Board and the Knoa Foundation Trustees is available here. 

Goettler has advised organizations across the pharmaceutical industry. He has worked extensively across the United States, Europe, and Asia, bringing a broad perspective to leadership and organizational culture. 

He holds an MBA from the University of Texas at Austin and a graduate degree from the Koblenz School of Corporate Management in Germany. 

About Knoa Pharma LLC 

Knoa Pharma was founded with a public health purpose to help abate the opioid crisis. That mission drives everything we do. We expand access to lifesaving overdose reversal medicines and deliver affordable treatments for opioid use disorder, while ensuring the safe and responsible distribution of medicines that are critical to patient care, including opioid analgesics. We also innovate to address unmet patient needs and enhance our robust generics portfolio. Owned by a not-for-profit foundation, every aspect of the business is centered on improving public health, saving lives, supporting recovery, and bringing forward medicines that make a meaningful difference. Learn more at www.knoapharma.com. 

Media Contact: 

News@pharma.com  

The post Knoa Pharma Board Appoints Michael Goettler as President and Chief Executive Officer appeared first on Knoa Pharma.

STAMFORD, CT – June 24, 2026 – Knoa Pharma LLC (“Knoa Pharma”), a public health-focused pharmaceutical company, and the Global Coalition for Adaptive Research (“GCAR”) announced that the first patient was randomized to the tinostamustine arm on GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447) in early April. In addition, the first patient in recurrent setting received the first dose of tinostamustine. Glioblastoma (GBM) is an aggressive brain cancer that is challenging to treat and currently has no cure.¹  

Tinostamustine is an investigational, first-in-class chemical entity that combines two potentially synergistic mechanisms of action, bifunctional alkylating activity and pan histone deacetylase inhibition (or HDAC inhibition). Tinostamustine has the potential to be a first-line treatment and is being investigated in patients with newly diagnosed GBM as an adjuvant therapy following standard treatment with surgery, chemotherapy and radiation, as well as in a limited cohort for patients in whom the disease has recurred following initial treatment.

Prior clinical research has evaluated tinostamustine in patients with MGMT promoter-unmethylated glioblastoma (uMGMT GBM). Patients with uMGMT GBM are associated with poor prognosis and limited treatment options. Nearly 15,000 people in the U.S. are diagnosed with GBM each year,² and 60% of those patients have uMGMT GBM.³

The trial, known as GBM AGILE, is a seamless phase 2/3 study conducted under a master protocol enabling multiple therapies or combinations of therapies from different pharmaceutical companies to be evaluated simultaneously against a shared control arm. With its innovative design and efficient operational infrastructure, data from GBM AGILE can potentially be used as the foundation for a new drug application (NDA) and registrations to the U.S. FDA and other health authorities.

“GBM AGILE was designed to accelerate the development of treatment options, which is why we’re honored to work with GCAR to determine whether tinostamustine could provide meaningful benefit to patients,” said Dr. Julie Ducharme, Vice President and Chief Scientific Officer, Knoa Pharma. “Encouraging findings from prior clinical studies support continued investigation.”

“Glioblastoma patient outcomes have seen minimal improvement over the past several decades,” said Dr. Meredith Buxton, CEO and President, GCAR. “The first patients randomized and dosed with tinostamustine marks an important milestone as we work to advance new treatment options and bring new hope to patients. By leveraging an adaptive platform design, we can assess promising treatments more rapidly than traditional clinical trials and make smarter, data-driven decisions sooner. GBM AGILE’s ability to evaluate therapies in newly diagnosed patients while simultaneously identifying signals in recurrent disease provides a powerful opportunity to accelerate the development of potential new options for patients with glioblastoma.”

In an earlier Phase 1 trial of tinostamustine in patients with uMGMT GBM, results showed tinostamustine to be tolerable at doses of 80 to 100 mg/m², with manageable side effects. While the Phase 1 study was not designed to demonstrate efficacy, exploratory analyses of progression-free and overall survival outcomes showed encouraging signals of clinical activity.

This press release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that tinostamustine will successfully complete development or gain FDA approval.

About Knoa Pharma LLC
Knoa Pharma makes important medicines safely and responsibly, while innovating to benefit patients and the public health. The company is dedicated to safely distributing medicines that are critical to patient care, enhancing its robust generics portfolio, addressing unmet medical needs, and supporting initiatives to address the opioid crisis. Our public minded mission enables us to expand access to lifesaving overdose reversal medicines and affordable treatments for opioid use disorder – at no profit. Owned by a not-for-profit foundation, everything we do is centered on improving public health, saving lives, supporting recovery, and bringing forward medicines that make a meaningful difference. Learn more at www.knoapharma.com. 

About Global Coalition for Adaptive Research (GCAR)
Global Coalition for Adaptive Research (GCAR) is a 501(c)(3) non-profit corporation pioneering collaborative, innovative trials to speed the discovery and development of cures. GCAR unites physicians, clinical researchers, advocacy and philanthropic organizations, biotech/pharma companies, health authorities, and other key stakeholders in healthcare to expedite research. As the sponsor of innovative trials, including master protocols and adaptive platform trials, GCAR is dedicated to the advancement of science by modernizing clinical trials that support more efficient, less costly drug development. To learn more about GCAR and its initiatives, visit gcaresearch.org and follow us on social media @GCAResearch

References

1. Glioblastoma (GBM). https://my.clevelandclinic.org/health/diseases/17032-glioblastoma. Accessed May 27, 2026.
2. Glioblastoma Brain Tumor Information. (n.d.). Glioblastoma Foundation. https://glioblastomafoundation.org/patients/glioblastoma-brain-tumor-information. Accessed May 27, 2026.
3. Liu, D., Yang, T., Ma, W., Wang, Y. (2022). Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation. Journal of Cancer, 13(1), 354-363. https://doi.org/10.7150/jca.63595. Accessed May 27, 2026.

The post Knoa Pharma and GCAR Announce First Newly Diagnosed Glioblastoma Patient Randomized in Phase 2/3 GBM AGILE Evaluation of Tinostamustine and First Recurrent Patient Dosed appeared first on Knoa Pharma.

STAMFORD, CT – June 22, 2026 – Knoa Pharma LLC (“Knoa Pharma”), a public health-focused pharmaceutical company dedicated to supporting patients and improving public health, will present its pipeline assets at the BIO International Convention 2026 in San Diego, Calif., on Tuesday, June 23, at 10:30 a.m. PT in Theatre 1. Knoa Pharma is actively seeking partnerships to advance the development of investigational therapeutics for multiple assets across several disease areas including genitourinary disorders, substance use disorders, and oncology. The company is discussing two assets, sunobinop and tinostamustine, both of which could present substantial revenue opportunities.* 

Tinostamustine is a novel, first-in-class investigational drug combining DNA alkylating activity and HDAC inhibition in a single molecule. It has the potential to be a first-line agent to treat patients with glioblastoma (GBM), a highly aggressive form of brain cancer. In Phase 1 studies as an adjuvant to standard chemoradiation, tinostamustine showed promising activity in difficult-to-treat newly diagnosed patients. The drug has received orphan drug designation from FDA and has the potential to be the first new pharmacologic treatment option for GBM in more than 20 years. In Phase 1/2 clinical trials, tinostamustine has also shown promise in multiple other solid and hematological tumors. 

Currently, tinostamustine is also a part of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447), sponsored by the Global Coalition for Adaptive Research. This is a seamless phase 2/3 study conducted under a master protocol enabling multiple therapies or combinations of therapies to be evaluated simultaneously against a shared control arm. With its innovative design and efficient operational infrastructure, data from GBM AGILE can potentially be used as the foundation for new drug applications and registrations to the U.S. FDA and other health authorities. 

Sunobinop is a novel, first-in-class nociceptin receptor agonist. The orally active investigational drug is in Phase 1/2 clinical development for multiple indications, including alcohol use disorder (AUD), interstitial cystitis/bladder pain syndrome (IC/BPS), and overactive bladder (OAB). Related to AUD, sunobinop is the only agent intended to address alcohol craving, consumption, and sleep issues; it has the potential to be the first new modality in AUD in almost 20 years. Related to OAB and IC/BPS, sunobinop is a novel, first-in-class agent that targets the sensory nerves in the bladder to affect urination and pain, in addition to reducing nocturia. Both conditions, OAB and IC/BPS, have significant unmet need 

“Our approach is grounded in rigorous R&D and a deep exploration of disease biology to advance innovative therapies for patients facing complex and underserved conditions,” said Dr. Julie Ducharme, Chief Scientific Officer, Knoa Pharma. “There are meaningful opportunities to collaborate along the way, and we look forward to partnering with those who share our ambitions.” 

“At the BIO International Convention, we will showcase our promising pipeline assets that have potential to benefit patients with unmet medical needs,” said David Saussy, Head of Licensing and Business Development at Knoa Pharma. “We look forward to and welcome the opportunity to engage with potential partners who share in our commitment to scientific innovation and developing meaningful treatment options.” 

Companies interested in learning more about Knoa Pharma’s pipeline and partnership opportunities are encouraged to connect with the team during the BIO International Convention 2026. For more information on pipeline products, e-mail partnering@Pharma.com. View the BIO presentation here.

*This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that sunobinop or tinostamustine will successfully complete development or gain FDA approval.

About Knoa Pharma LLC
Knoa Pharma makes important medicines safely and responsibly, while innovating to benefit patients and the public health. The company is dedicated to safely distributing medicines that are critical to patient care, enhancing its robust generics portfolio, addressing unmet medical needs, and supporting initiatives to address the opioid crisis. Our public minded mission enables us to expand access to lifesaving overdose reversal medicines and affordable treatments for opioid use disorder – at no profit. Owned by a not-for-profit foundation, everything we do is centered on improving public health, saving lives, supporting recovery, and bringing forward medicines that make a meaningful difference. Learn more at www.knoapharma.com. 

Media Contact:
news@pharma.com 

The post Knoa Pharma to Present Pipeline Assets at BIO International Convention 2026 appeared first on Knoa Pharma.

STAMFORD, Conn. – May 1, 2026 – Knoa Pharma LLC (“Knoa Pharma”) today begins operations as an independent company created to ensure safe access to medicines that are critical to patient care and to support communities with a purpose dedicated to abating the opioid crisis and improving public health. The company emerged following the conclusion of Purdue Pharma L.P.’s Chapter 11 proceedings on May 1, 2026, at which time Purdue permanently ceased operations. Established with the key stakeholders and creditor constituencies, including the United States Department of Justice, the States, Territories and other governmental entities, personal injury victims, and other stakeholders, Knoa Pharma was designed with strong governance, clear accountability, and a commitment to serving the public good. 

Knoa Pharma is 100% owned by the newly established not-for-profit Knoa Foundation, a 501(c)(4). This governance structure, which will ensure strong oversight of the company as it delivers on its purpose, establishes two independent boards comprising individuals who have no prior association with Purdue: 

• The Knoa Foundation Board of Trustees, which includes three notable leaders in public health, drug policy, and large-scale philanthropy; and, 

• The Knoa Pharma Board of Directors, which includes four leaders with expertise in pharmaceuticals, operations, ethics and compliance, corporate governance, audit, and finance. 

As a public health-focused pharmaceutical company, Knoa Pharma will safely and responsibly manufacture existing medicines, including opioid analgesics, to address critical patient needs, and will continue to advance its branded and generics portfolio to treat a range of medical conditions. Importantly, Knoa Pharma will not promote opioid products. The company operates under a strict operating injunction with oversight by an independent monitor¹ to ensure it provides these medicines in the safest possible manner that limits the risk of diversion. 

Value generated through Knoa Pharma’s business will be used to support opioid abatement efforts across the United States, including the company’s initiatives to provide overdose reversal agents and opioid use disorder medicines at no profit.  

“Knoa Pharma’s unique model ensures that the company’s resources directly support public health,” said Dr. Paul Rothman, Chair of the Knoa Foundation Board of Trustees. “Through not‑for‑profit access to overdose reversal medicines and treatments for opioid use disorder, Knoa Pharma is committed to providing care and saving lives in communities most affected by the opioid crisis.” 

“Knoa Pharma launches with the scientific expertise, governance, and operational discipline needed to deliver essential medicines safely and responsibly,” said Dr. Norbert Riedel, Chair of the Knoa Pharma Board of Directors. “Our focus now is on building a sustainable and accountable company that can meet critical patient needs and support the broader public health purpose entrusted to us.” 

Together, the independent Trustees of the Knoa Foundation and the members of the Knoa Pharma Board of Directors will ensure that Knoa Pharma operates responsibly, sustainably, and transparently, and in accordance with its public health purpose. 

Advancing Knoa Pharma’s Public Health Initiatives
Knoa Pharma is committed to addressing critical public health challenges related to the opioid crisis through evidence-based efforts focused on expanding access to lifesaving overdose reversal tools and medications used to treat opioid use disorder. These public health initiatives operate under a not-for-profit model designed to make treatments available at or below the cost of production. 

Foundation Trustees and Board of Directors Biographies 

Knoa Foundation Board of Trustees: 

Paul B. Rothman, MD, Board Chair
Paul Rothman is the former CEO of Johns Hopkins University School of Medicine and Dean of the Medical Faculty. At Johns Hopkins, Dr. Rothman oversaw one of the world’s leading academic medical centers, with deep involvement in clinical care, research, and public health policy. He is a member of the National Academy of Medicine and serves on the Board of Directors of LabCorp (NYSE: LH) and Merck (NYSE: MRK). Dr. Rothman previously served as Dean of Carver College of Medicine at the University of Iowa and Professor of Medicine and Chief of Pulmonary, Allergy and Critical Care at Columbia University. 

Rahul Gupta, MD, MPH, MBA
Rahul Gupta is President of GATC Health, an AI-driven technology company focused on drug discovery, precision medicine, and predictive analytics. He previously served as Director of the White House Office of National Drug Control Policy (ONDCP), where, following Senate confirmation, he became the first physician to lead the office and coordinated a $44 billion annual budget across 19 federal agencies while overseeing the nation’s drug policy. Dr. Gupta earlier served as Chief Medical and Health Officer and Senior Vice President at March of Dimes, advancing national and global maternal and infant health priorities. He also served as West Virginia Health Commissioner under two Governors and as a local health commissioner, leading statewide public health transformation and complex crisis response efforts. Dr. Gupta serves as clinical professor of medicine at Georgetown University School of Medicine and visiting faculty at the Harvard T.H. Chan School of Public Health. He continues to practice medicine. 

David Saltzman
David Saltzman is the Co-Founder of the Atria Health and Research Institute, and Chairman and Co-Founder of the Atria Research and Global Health Institute, a not-for-profit organization dedicated to eradicating medical inequity. Additionally, Mr. Saltzman is the Co-Founder, Director and former longtime Executive Director of The Robin Hood Foundation, New York City’s largest local poverty-fighting philanthropy. He serves as a Director of Rithm Capital (NYSE: RITM) and iMentor. Mr. Saltzman previously served as a Director of the Hershey Trust Company and the Milton Hershey School, Zearn, the Relay Graduate School of Education and a number of other for-profit and not-for-profit organizations. Early in his career, he helped run some of the earliest AIDS education programs for the NYC Department of Health. 

Knoa Pharma Board of Directors: 

Norbert Riedel, Ph.D., Board Chair
Dr. Norbert Riedel is former Executive Chairman and CEO of Aptinyx (formerly NASDAQ: APTX). He is currently Chairman of Eton Pharmaceuticals and a Board member of Jazz Pharmaceuticals, Angitia Biopharmaceuticals, Atsena Therapeutics, and the non-profit Illinois Biotechnology Innovation Organization. Dr. Riedel previously served as CEO and President of Naurex; Corporate VP and Chief Science and Innovation Officer at Baxter International; Head of Worldwide Biotechnology at Hoechst Marion Roussel (now Sanofi); and Director of Ariad Pharmaceuticals, Cerevel Therapeutics, and Oscient Pharmaceuticals. Dr. Riedel is a member of the Austrian Academy of Sciences and served on Governor Pat Quinn’s Illinois Innovation Council. He is an adjunct professor at Boston University School of Medicine and Northwestern University’s Feinberg School of Medicine. Previously, he was Associate Professor of Medicines at Boston University School of Medicine and visiting professor at the Massachusetts Institute of Technology. Dr. Riedel holds a Ph.D. in Biochemistry from the University of Frankfurt and was a postdoctoral fellow at Harvard. 

Karen Griffin
Karen Griffin is Executive Vice President and Chief Risk Officer at Mastercard (NYSE: MA) and a member of the Executive Leadership Team and Management Committee. Prior to this role, she was Executive Vice President and Chief Compliance Officer. Ms. Griffin was previously Senior Vice President and Chief Compliance Officer at Visa (NYSE:V), and Vice President of the Office of Business Conduct at Alcatel-Lucent. She has also held several business leadership roles at Lucent Technologies and AT&T including Product Management, Customer Delivery and Engineering. Ms. Griffin currently serves as Vice Chair of the ICC Global Commission on Business Integrity and is a member of the World Economic Forum Steering Committee for Partnering Against Corruption Initiative. She is a long-standing member of the B20 Integrity and Compliance Task Force across multiple presidencies. Ms. Griffin previously served as a member of the Mastercard Europe Board of Directors, the World Economic Forum Global Future Council on Good Governance, and Co-Chair of the B20 Integrity and Compliance Task Force. 

Patricia Lang, HR/Comp Chair
Patricia Lang is Senior Vice President and Chief Human Resources Officer Emeritus at Enovis (NYSE: ENOV), a global medical device company where she recently served as Senior Vice President and Chief Human Resources Officer. She previously served as Chief Human Resources Officer of Colfax, a global industrial compounder with $3.3 billion in revenue, and as Chief People Officer for Diebold Nixdorf (NYSE:DBD), a financial and retail technology company with $3.7 billion in revenue. In her more than 35 years in human resources and related fields, Ms. Lang has held leadership positions at companies such as Mylan Pharmaceuticals, CONSOL Energy, Mercer Consulting, and Cigna. She serves on the American Bath Group Board of Directors where she is a member of the Compensation Committee. 

Mike McHale, Audit Chair
Mike McHale is a retired Deals and Global Client Relationship Partner at PricewaterhouseCoopers (PwC). In his more than 35 years at PwC, Mr. McHale provided a broad range of mergers and acquisitions services including industry strategic assessments, business and financial due diligence, accounting and tax structure, post-merger integration, and value capture to corporations in a variety of industries. He was also responsible for overseeing the audit, tax, and consulting services across global fund and portfolio company structures. Mr. McHale is a Certified Public Accountant in New York and an adjunct instructor at Colby College. 

Interim CEO Appointment
Marc Kesselman, previously the company’s Chief Legal Officer, EVP Strategy & Corporate Affairs, has been appointed to serve as President & Chief Executive Officer of Knoa Pharma while a comprehensive search is conducted for a permanent CEO. Mr. Kesselman brings extensive senior leadership experience across government, legal, and corporate roles. He has served in the United States Department of Justice, the White House, and as the Senate-confirmed General Counsel of the United States Department of Agriculture; has held senior positions at global companies; and has played a central role in shaping Knoa Pharma’s public health-focused structure. 

About Knoa Pharma LLC
Knoa Pharma makes important medicines safely and responsibly, while innovating to benefit patients and the public health. The company is dedicated to safely distributing medicines that are critical to patient care, enhancing its robust generics portfolio, addressing unmet medical needs, and supporting initiatives to address the opioid crisis. Our public minded mission enables us to expand access to lifesaving overdose reversal medicines and affordable treatments for opioid use disorder – at no profit. Owned by a not-for-profit foundation, everything we do is centered on improving public health, saving lives, supporting recovery, and bringing forward medicines that make a meaningful difference. Learn more at www.knoapharma.com. 

Media Contact:
news@pharma.com 

The post Knoa Pharma Begins Operations as a New, Public Health-Focused Company Dedicated to Supporting Patients and Abating the Opioid Crisis appeared first on Knoa Pharma.